JPMorgan Chase and Co. lowered its position in Harrow, Inc. (NASDAQ: HROW) by 53.9% during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 36,167 shares of the company's stock after selling 42,246 shares during the quarter. JPMorgan Chase and Co. owned
NASHVILLE, Tenn., March 24, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the pricing of its private offering (the “Offering”) of $50.0 million aggregate principal amount of 8.625% senior unsecured notes due 2030 (the “2030 Notes”).
Opaleye Management Inc. disposed of 198,572 shares indirectly across two days, with a transaction value of roughly $7.8 million based on weighted average prices of $39.15 on March 3 and $39.67 on March 4. Following the transactions, Opaleye Management Inc. retains an indirect position of approximately 3.68 million shares across both vehicles.
NASHVILLE, Tenn., March 24, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it intends to offer, subject to market and certain other conditions, an additional $50.0 million in aggregate principal amount of its 8.625% senior unsecured notes due 2030 (the "2030 Notes"). The 2030 Notes will be guaranteed on a senior unsecured basis by the Company's existing and future wholly-owned domestic restricted subsidiaries and any of its other restricted subsidiaries that guarantees or co-issues any of its indebtedness or any indebtedness of any of its subsidiaries that guarantees the 2030 Notes, subject to certain exceptions. The 2030 Notes will be issued as additional notes under the same indenture governing the $250,000,000 aggregate principal amount of 2030 Notes that were issued on September 12, 2025 (the “Existing Notes”), will be treated as a single series with the Existing Notes and will have the same terms as the Existing Notes other than with respect to the date of issuance and the issue price.
NASHVILLE, Tenn., March 18, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that three scientific abstracts highlighting its commercial products VEVYE® (cyclosporine ophthalmic solution) 0.1% and ILEVRO® (nepafenac ophthalmic suspension) 0.3% have been accepted for presentation at the American Society of Cataract and Refractive Surgery (ASCRS) 2026 Annual Meeting, taking place April 10–13 at the Walter E. Washington Convention Center in Washington, D.C.
Harrow, Inc. is rapidly evolving into a dominant US ophthalmic pharma player, with a 30-fold revenue increase since 2015 and strong operating leverage. HROW's recent 35% stock pullback post-Q4 2025 is attributed to conservative 2026 guidance, not deteriorating fundamentals, presenting a compelling buying opportunity. Vevye and Iheezo, HROW's flagship drugs, are set for significant revenue acceleration through expanded insurance coverage, salesforce doubling, and clinical trial catalysts.
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
Harrow Inc. (NASDAQ: HROW) posted mixed results for the fourth quarter on Tuesday.
NASHVILLE, Tenn., March 04, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will present at Leerink Partner's 2026 Global Healthcare Conference on Tuesday, March 10, 2026, at 8:40 AM ET, in Miami, Florida.
Harrow (HROW) is downgraded to 'Sell' as recent earnings reveal persistent low margins and overvaluation despite a 25% share price drop. FY25 revenue grew 36% YoY to $272.3M, but missed ambitious guidance and was aided by non-recurring customer stocking; future growth is back-loaded and costly. HROW's high debt load and rising interest expenses erode cash generation, with management relying on increased S&M spend and acquisitions for growth.
